Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting

April 8, 2024

https://www.globenewswire.com/news-release/2024/04/08/2859598/0/en/Cellectis-Announces-Two-Poster-Presentations-on-Novel-TALEN-Editing-Process-for-Gene-Correction-and-Gene-Insertion-in-HSPCs-at-the-ASGCT-Annual-Meeting.html

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that preliminary data exploring novel TALEN® editing process in hematopoietic stem and progenitor cells (HSPCs) will be presented at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, to be held in Baltimore, Maryland, on May 7-11, 2024.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.